Skip to content
Search

Latest Stories

Jug Jugg Jeeyo: Second shooting schedule of the film delayed due to the lockdown

By Murtuza Iqbal

Last year, it was announced that Anil Kapoor, Neetu Kapoor, Varun Dhawan, and Kiara Advani will be seen in a film titled Jug Jugg Jeeyo. The film is produced by Karan Johar and directed by Raj Mehta.


The first shooting schedule of the movie took place in Chandigarh in 2020 and during the shoot Varun, Neetu Kapoor, and director Raj Mehta were tested positive for Covid-19. However, after they recovered, the schedule was successfully wrapped up.

Now, the second schedule of the film was supposed to kickstart this month, however, due to the lockdown in Maharashtra, the shoot has been delayed.

While talking to Mid-day, Mehta stated, “Almost 60 percent of the film is pending. We were supposed to shoot this month, but are faced with a challenge again.”

“We had shot the first schedule right after the first wave of the pandemic. It was difficult, and we did have cases on the set. But at the end of the day, you have to take safety precautions and trust the team,” he added.

Well, due to the lockdown shooting of films has been stalled. However, many filmmakers have decided to shoot their movies in a state where the lockdown has not been imposed.

Talking about Jug Jugg Jeeyo, the film will mark Neetu Kapoor’s comeback on the big screen after a gap of eight years and for the first time, she and Anil Kapoor have been paired opposite each other.

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less